Record #241525 - GSI Repository

MAGIF

Faron leading the way in macrophage guided immunotherapy

Grant period	2020-10-01 - 2022-09-30
Funding body	European Union
Call number	H2020-EIC-SMEInst-2018-2020-3
Grant number	960914
Identifier	G:(EU-Grant)960914

Note: Cancer is a leading cause of death in the world despite relentless research to discover new treatments. There were over 18M new cancer cases and 9.6M deaths due to cancer worldwide in 2018. Human suffering due to cancer is devastating. The impact and cost of cancer to society is extensive and complex. Faron aims to provide a new solution that could replace several currently used ineffective cancer treatments. Faron is a Finnish biotech company committed to high-quality R&D to fulfil the company’s mission of saving lives. Faron’s game-changing immuno-oncology (IO) treatment CLEVEGEN revolves around a key immunosuppressive molecule named Clever-1 on tumour associated macrophages, responsible for cancer growth and spread. CLEVEGEN is an anti-Clever-1 antibody that brakes the immunosuppressive tolerance of tumours and activates the patient’s immune defences against cancer. The first results from Faron’s first-in-human clinical trial with CLEVEGEN are very positive with early clinical benefits with a switch in patients’ immune profile towards immune stimulation leading to tumour shrinkage in cancer types where nothing has worked before. The early evidence of a clinical response to CLEVEGEN strengthens Faron’s value proposition of it as a break-through cancer treatment. CLEVEGEN has major advantages compared to other IO treatments. Most importantly, patients who would benefit from the treatment can be screened. This would prevent futile treatment and deliver savings in healthcare resources and cost. The CLEVEGEN program is focused on deadly cancer types without effective treatment options and over 3.5M new cases and 2.3M deaths yearly. The market opportunity is clear. With transition to other cancers and the possibility of becoming the first line of therapy due to an exceptional safety profile, the potential up-scale of CLEVEGEN is enormous. There is nothing like CLEVEGEN on the market. CLEVEGEN could secure Faron a world-leading position in the new wave of macrophage guided immunotherapy.

Recent Publications

There are no publications

Record created 2021-10-10, last modified 2023-02-12

Similar records

Add to personal basket
Export as Author List with IDs BibTeX (UTF-8), EndNote XML, EndNote Text, RIS, MARC, Print MARC, MARCXML, DC,
Request correction
Submit fulltext

GSI Homepage \| GSI Library \| English Deutsch \| guest :: login GSI Repository
Search	Submit	Personalize Your alerts Your baskets Your searches	Help